NCT05548296 2026-03-24
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Acrivon Therapeutics
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06597565 2025-10-20
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT02873975 2022-10-21
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02203513 2022-09-10
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03414047 2022-08-19
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02735980 2020-03-17
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed